Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: INCY

Incyte Corporation

Healthcare | Biotechnology

Market prices for INCY are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$7.08

Incyte Corporation (NASDAQ: INCY) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:50 UTC.

What Incyte Corporation does

The company manufactures pharmaceutical products including JAKAFI, ICLUSIG, MONJUVI/MINJUVI, PEMAZYRE, ZYNYZ, NIKTIMVO, and OPZELURA that compete with therapies from major pharmaceutical and biotechnology companies and specialty pharmaceutical firms. JAKAFI faces competition from generic manufacturers who have filed applications seeking approval of generic versions, and the company has initiated patent infringement litigation against these manufacturers in federal court; some cases have been settled while others remain pending.

Summarized from Incyte Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$7.08
Return on equity24.90%

Revenue, margins & earnings

FY2021 Revenue: $2.99B — margin split not shown (non-operating gains)$2.99BFY2021FY2022 Net income: $341MFY2022 Taxes & interest: $239MFY2022 Operating costs: $2.82B$3.39BFY2022FY2023 Net income: $598MFY2023 Operating costs: $3.08B$3.70BFY2023FY2024 Operating costs: $4.18B$4.24BFY2024FY2025 Net income: $1.29BFY2025 Taxes & interest: $228MFY2025 Operating costs: $3.63B$5.14BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-19
  • 2026-10-19President, Global Head of R&DEmployee Stock Option (right to buy)Option exercise-423—
  • 2026-10-19President, Global Head of R&DOption exercise423$26.1K
  • 2026-10-19President, Global Head of R&DEmployee Stock Option (right to buy)Option exercise-455—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Incyte Corporation do?

The company manufactures pharmaceutical products including JAKAFI, ICLUSIG, MONJUVI/MINJUVI, PEMAZYRE, ZYNYZ, NIKTIMVO, and OPZELURA that compete with therapies from major pharmaceutical and biotechnology companies and specialty pharmaceutical firms.

When did INCY last file with the SEC?

Incyte Corporation's most recent SEC filing on record is a 8-K filed 2026-07-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:50 UTC. This page is also available as JSON at /api/data?ticker=INCY and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for INCY and 5,000+ tickers.

Create a free account — keep INCY
For your agent
GET /api/data?ticker=INCY

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt